A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
← catalyst calendarSponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
44actual
Sites
47
Countries
Australia, Canada, France +6
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-04-17 | actual | When the study began enrolling |
| Primary completion | 2025-11-25 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-03-28 | estimated | The whole study's end, after follow-up |
| First posted | 2024-02-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Cardiomyopathy, Hypertrophic
Interventions
- Drug: Mavacamten — also filed as BMS-986427
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFChange from baseline in Valsalva left ventricular outflow tract (LVOT) (VLVOT) gradient
measured At Week 28
Publications
- PMID 41910394 — linked by the registry
- PMID 41038603 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed